HC Wainwright & Co. Initiates Coverage On MapLight Therapeutics with Buy Rating, Announces Price Target of $45
Benzinga Newsdesk 6 months ago
NewsPrice TargetInitiationAnalyst Ratings
HC Wainwright & Co. analyst Raghuram Selvaraju initiates coverage on MapLight Therapeutics (NASDAQ:MPLT) with a Buy rating and announces Price Target of $45.
HC Wainwright & Co. analyst Raghuram Selvaraju initiates coverage on MapLight Therapeutics (NASDAQ:MPLT) with a Buy rating and announces Price Target of $45.